bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Exploiting Metabolic Defects in Glioma with Nanoparticle-Encapsulated NAMPT Inhibitors
Authors: Murray Matthew A. , Noronha Katelyn J. , Wang Yazhe , Friedman Anna P. , Paradkar Sateja , Suh Hee-Won , Sundaram Ranjini K. , Brenner Charles , Saltzman W.M. , Bindra Ranjit S.
Published: August 2024

Abstract
The treatment of primary central nervous system tumors is challenging due to the blood–brain barrier and complex mutational profiles, which is associated with low survival rates. However, recent studies have identified common mutations in gliomas [isocitrate dehydrogenase (IDH)-wild-type and mutant, WHO grades II–IV; with grade IV tumors referred to as glioblastomas (GBM)]. These mutations drive epigenetic changes, leading to promoter methylation at the nicotinic acid phosphoribosyl transferase (NAPRT) gene locus, which encodes an enzyme involved in generating NAD+. Importantly, NAPRT silencing introduces a therapeutic vulnerability to inhibitors targeting another NAD+ biogenesis enzyme, nicotinamide phosphoribosyl transferase (NAMPT), rationalizing a treatment for these malignancies. Multiple systemically administered NAMPT inhibitors (NAMPTi) have been developed and tested in clinical trials, but dose-limiting toxicities—including bone marrow suppression and retinal toxicity—have limited their efficacy. Here, we report a novel approach for the treatment of NAPRT-silenced GBMs using nanoparticle (NP)-encapsulated NAMPTis administered by convection-enhanced delivery (CED). We demonstrate that GMX1778 (a NAMPTi) can be formulated in degradable polymer NPs with retention of potency for NAMPT inhibition and anticancer activity in vitro, plus sustained drug release in vitro and in vivo. Direct injection of these drugs via CED into the brain is associated with reduced retinal toxicity compared with systemic administration. Finally, we show that CED of NP-encapsulated GMX1778 to NAPRT-silenced intracranial GBM xenografts in mice exhibit significant tumor growth delay and extends survival. These data support an approach to treat gliomas harboring defects in NAD+ metabolism using CED of NP-encapsulated NAMPTis to greatly improve the therapeutic index and treatment efficacy for this class of drugs.
Data from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Authors: Satomaa Tero , Pynnönen Henna , Aitio Olli , Hiltunen Jukka O. , Pitkänen Virve , Lähteenmäki Tuula , Kotiranta Titta , Heiskanen Annamari , Hänninen Anna-Liisa , Niemelä Ritva , Helin Jari , Kuusanmäki Heikki , Vänttinen Ida , Rathod Ramji , Nieminen Anni I. , Yatkin Emrah , Heckman Caroline A. , Kontro Mika , Saarinen Juhani
Published: August 2024

Abstract
CD33 (Siglec-3) is a cell surface receptor expressed in approximately 90% of acute myeloid leukemia (AML) blasts, making it an attractive target for therapy of AML. Although previous CD33-targeting antibody–drug conjugates (ADC) like gemtuzumab ozogamicin (GO, Mylotarg) have shown efficacy in AML treatment, they have suffered from toxicity and narrow therapeutic window. This study aimed to develop a novelADCwith improved tolerability and a wider therapeutic window. GLK-33 consists of the anti-CD33 antibody lintuzumab and eight mavg-MMAU auristatin linkerpayloads per antibody. The experimental methods included testing in cell cultures, patient-derived samples, mouse xenograft models, and rat toxicology studies. GLK-33 exhibited remarkable efficacy in reducing cell viability within CD33-positive leukemia cell lines and primary AML samples. Notably, GLK-33 demonstrated antitumor activity at single dose as low as 300 mg/kg in mice, while maintaining tolerability at single dose of 20 to 30 mg/kg in rats. In contrast with both GO and lintuzumab vedotin, GLK-33 exhibited a wide therapeutic window and activity against multidrug-resistant cells. The development of GLK-33 addresses the limitations of previous ADCs, offering a wider therapeutic window, improved tolerability, and activity against drug-resistant leukemia cells. These findings encourage further exploration of GLK-33 in AML through clinical trials.
Supplementary Table 4 from A Linear Relationship between the Number of Cancers among First-Degree Relatives and the Risk of Multiple Primary Cancers
Authors: He Shisi , Barry Kathryn H. , Mitchell Braxton D. , Chen Shuo , Zhang Yuji , Beane Freeman Laura E. , Berndt Sonja I.
Published: August 2024

Supplementary Table 4 shows the risk of multiple primary cancers and family history of cancer among adulthood cancer survivors in the PLCO Cancer Screening Trial
Supplementary Table 3 from A Linear Relationship between the Number of Cancers among First-Degree Relatives and the Risk of Multiple Primary Cancers
Authors: He Shisi , Barry Kathryn H. , Mitchell Braxton D. , Chen Shuo , Zhang Yuji , Beane Freeman Laura E. , Berndt Sonja I.
Published: August 2024

Supplementary Table 3 shows the risk of a single primary cancer associated with family history of cancer among first-degree relatives in the PLCO Cancer Screening Trial
Supplemental Table 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Authors: Ho Chi-Lee C. , Gilbert Michael B. , Urtecho Guillaume , Lee Hyoungjoo , Drew David A. , Klempner Samuel J. , Cho Jin S. , Ryan Thomas J. , Rustgi Naryan , Lee Hyuk , Lee Jeeyun , Caraballo Alexander , Magicheva-Gupta Marina V. , Rios Carmen , Shin Alice E. , Tseng Yuen-Yi , Davis Jeremy L. , Chung Daniel C. , Chan Andrew T. , Wang Harris H. , Ryeom Sandra
Published: August 2024

Supplemental Table 2 describes the biopsy information of patient derived organoid cell lines.
Supplemental Table 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Authors: Ho Chi-Lee C. , Gilbert Michael B. , Urtecho Guillaume , Lee Hyoungjoo , Drew David A. , Klempner Samuel J. , Cho Jin S. , Ryan Thomas J. , Rustgi Naryan , Lee Hyuk , Lee Jeeyun , Caraballo Alexander , Magicheva-Gupta Marina V. , Rios Carmen , Shin Alice E. , Tseng Yuen-Yi , Davis Jeremy L. , Chung Daniel C. , Chan Andrew T. , Wang Harris H. , Ryeom Sandra
Published: August 2024

Supplemental Table 1 lists the age and sex of stool donors.
Supplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Authors: Ho Chi-Lee C. , Gilbert Michael B. , Urtecho Guillaume , Lee Hyoungjoo , Drew David A. , Klempner Samuel J. , Cho Jin S. , Ryan Thomas J. , Rustgi Naryan , Lee Hyuk , Lee Jeeyun , Caraballo Alexander , Magicheva-Gupta Marina V. , Rios Carmen , Shin Alice E. , Tseng Yuen-Yi , Davis Jeremy L. , Chung Daniel C. , Chan Andrew T. , Wang Harris H. , Ryeom Sandra
Published: August 2024

Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.
Supplemental Figure 3 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Authors: Ho Chi-Lee C. , Gilbert Michael B. , Urtecho Guillaume , Lee Hyoungjoo , Drew David A. , Klempner Samuel J. , Cho Jin S. , Ryan Thomas J. , Rustgi Naryan , Lee Hyuk , Lee Jeeyun , Caraballo Alexander , Magicheva-Gupta Marina V. , Rios Carmen , Shin Alice E. , Tseng Yuen-Yi , Davis Jeremy L. , Chung Daniel C. , Chan Andrew T. , Wang Harris H. , Ryeom Sandra
Published: August 2024

Supplemental Figure 3 shows the progression of disease between 4and 8 week old TCON mice and the amount of ACTN4 and DPP4 in stomach tissue.
Supplemental Figure 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Authors: Ho Chi-Lee C. , Gilbert Michael B. , Urtecho Guillaume , Lee Hyoungjoo , Drew David A. , Klempner Samuel J. , Cho Jin S. , Ryan Thomas J. , Rustgi Naryan , Lee Hyuk , Lee Jeeyun , Caraballo Alexander , Magicheva-Gupta Marina V. , Rios Carmen , Shin Alice E. , Tseng Yuen-Yi , Davis Jeremy L. , Chung Daniel C. , Chan Andrew T. , Wang Harris H. , Ryeom Sandra
Published: August 2024

Supplemental Figure 1 shows the effect using different lysis buffers has on protein identification in stool protein mass spectrometry.
Data from A Linear Relationship between the Number of Cancers among First-Degree Relatives and the Risk of Multiple Primary Cancers
Authors: He Shisi , Barry Kathryn H. , Mitchell Braxton D. , Chen Shuo , Zhang Yuji , Beane Freeman Laura E. , Berndt Sonja I.
Published: August 2024

Abstract
With advances in the early detection and treatment of cancer, the incidence of multiple primary cancers (MPC) or second primary cancers has increased over time. Characterization of etiologic risk factors, including family history of cancer, within the general population is critical for assessing MPC risk in patients. We examined the association between family history of cancer among first-degree relatives and MPC risk in a prospective study of 139,958 participants from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cox proportional hazard models were used to calculate HRs and 95% confidence intervals (95% CI), adjusting for potential confounders. Over a median follow-up of 16 years (IQR: 11–19 years), 6,170 participants were diagnosed with MPC. Having a family history of cancer increased the risk of MPC by 18% (HR, 1.18; 95% CI, 1.12–1.24). A positive linear trend was observed between the reported number of cancers in the family history and MPC risk with HRs (95% CI) of 1.13 (1.07–1.20), 1.23 (1.14–1.33), 1.29 (1.15–1.45), and 1.42 (1.20–1.70) for one, two, three, and four or more cancers among first-degree relatives, respectively (Ptrend = 2.36 × 10−13). No significant differences were observed by cancer histology or specific cancer types reported in the family history. Our study demonstrates that the family history of cancer is an important risk factor for the development of MPCs and that a comprehensive assessment of the number of cancers reported among first-degree relatives may identify those at higher risk who may benefit from targeted cancer prevention and screening strategies.

Prevention Relevance: Our study makes a substantial contribution to the understanding of risk factors for MPCs in the general population. It demonstrates that individuals with a strong family history of cancer are at higher risk for MPCs and may benefit from more targeted cancer prevention and screening interventions.
Supplementary Table S2 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
Authors: Mehta Naveen K. , Rakhra Kavya , Meetze Kristan A. , Li Bochong , Momin Noor , Chang Jason Y.H. , Wittrup K. Dane , Baeuerle Patrick A. , Michaelson Jennifer S.
Published: August 2024

Antibodies used for FACS analysis (human)
Supplementary Figure S9 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
Authors: Mehta Naveen K. , Rakhra Kavya , Meetze Kristan A. , Li Bochong , Momin Noor , Chang Jason Y.H. , Wittrup K. Dane , Baeuerle Patrick A. , Michaelson Jennifer S.
Published: August 2024

Immunophenotyping of peripheral blood
Supplementary Figure S3 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
Authors: Mehta Naveen K. , Rakhra Kavya , Meetze Kristan A. , Li Bochong , Momin Noor , Chang Jason Y.H. , Wittrup K. Dane , Baeuerle Patrick A. , Michaelson Jennifer S.
Published: August 2024

Serum IL2 and IL12 levels measured up to 72 hours after injection with single cytokine fusion or mCLN-617
Supplementary Figure S12 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
Authors: Mehta Naveen K. , Rakhra Kavya , Meetze Kristan A. , Li Bochong , Momin Noor , Chang Jason Y.H. , Wittrup K. Dane , Baeuerle Patrick A. , Michaelson Jennifer S.
Published: August 2024

Gating scheme for flow cytometry data analysis
Supplementary Figure S10 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity
Authors: Mehta Naveen K. , Rakhra Kavya , Meetze Kristan A. , Li Bochong , Momin Noor , Chang Jason Y.H. , Wittrup K. Dane , Baeuerle Patrick A. , Michaelson Jennifer S.
Published: August 2024

Analysis of dendritic cells in response to mCLN-617
Supplementary Table 2 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity
Authors: Zhu Manman , Wu Yongjian , Zhu Tianchuan , Chen Jian , Chen Zhenxing , Ding Hanxi , Tan Siyi , He Jianzhong , Zeng Qi , Huang Xi
Published: August 2024

Supplementary Table 2
Supplementary Figure 8 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity
Authors: Zhu Manman , Wu Yongjian , Zhu Tianchuan , Chen Jian , Chen Zhenxing , Ding Hanxi , Tan Siyi , He Jianzhong , Zeng Qi , Huang Xi
Published: August 2024

Supplementary Figure 8
Supplementary Figure 7 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity
Authors: Zhu Manman , Wu Yongjian , Zhu Tianchuan , Chen Jian , Chen Zhenxing , Ding Hanxi , Tan Siyi , He Jianzhong , Zeng Qi , Huang Xi
Published: August 2024

Supplementary Figure 7
Supplementary Figure 5 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity
Authors: Zhu Manman , Wu Yongjian , Zhu Tianchuan , Chen Jian , Chen Zhenxing , Ding Hanxi , Tan Siyi , He Jianzhong , Zeng Qi , Huang Xi
Published: August 2024

Supplementary Figure 5
Supplementary Figure 4 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity
Authors: Zhu Manman , Wu Yongjian , Zhu Tianchuan , Chen Jian , Chen Zhenxing , Ding Hanxi , Tan Siyi , He Jianzhong , Zeng Qi , Huang Xi
Published: August 2024

Supplementary Figure 4
Supplementary Figure 3 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity
Authors: Zhu Manman , Wu Yongjian , Zhu Tianchuan , Chen Jian , Chen Zhenxing , Ding Hanxi , Tan Siyi , He Jianzhong , Zeng Qi , Huang Xi
Published: August 2024

Supplementary Figure 3
Supplementary Figure 2 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity
Authors: Zhu Manman , Wu Yongjian , Zhu Tianchuan , Chen Jian , Chen Zhenxing , Ding Hanxi , Tan Siyi , He Jianzhong , Zeng Qi , Huang Xi
Published: August 2024

Supplementary Figure 2
Supplementary Figure 13 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity
Authors: Zhu Manman , Wu Yongjian , Zhu Tianchuan , Chen Jian , Chen Zhenxing , Ding Hanxi , Tan Siyi , He Jianzhong , Zeng Qi , Huang Xi
Published: August 2024

Supplementary Figure 13
Supplementary Figure 1 from Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity
Authors: Zhu Manman , Wu Yongjian , Zhu Tianchuan , Chen Jian , Chen Zhenxing , Ding Hanxi , Tan Siyi , He Jianzhong , Zeng Qi , Huang Xi
Published: August 2024

Supplementary Figure 1
Figure S9 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Authors: Liao Rosy , Hsu Jocelyn Y. , Aboelella Nada S. , McKeever Joshua A. , Thomas-Toth Anika T. , Koh Andrew S. , LaBelle James L.
Published: August 2024

Supplementary Figure S9. Tamoxifen does not alter T cell subpopulation cells or MC38 growth
Figure S8 from Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade
Authors: Liao Rosy , Hsu Jocelyn Y. , Aboelella Nada S. , McKeever Joshua A. , Thomas-Toth Anika T. , Koh Andrew S. , LaBelle James L.
Published: August 2024

Supplementary Figure S8. Log2FoldChange heatmap of commonly dysregulated genes in Bcl2 KO or venetoclax-treated WT Tregs compared to vehicle controls.
Figure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Authors: Fredon Maxime , Poussard Margaux , Biichlé Sabeha , Bonnefoy Francis , Mantion Charles-Frédéric , Seffar Evan , Renosi Florian , Bôle-Richard Elodie , Boidot Romain , Chevrier Sandrine , Anna François , Loustau Maria , Caumartin Julien , Gonçalves-Venturelli Mathieu , Robinet Eric , Saas Philippe , Deconinck Eric , Daguidau Etienne , Roussel Xavier , Godet Yann , Adotévi Olivier , Angelot-Delettre Fanny , Galaine Jeanne , Garnache-Ottou Francine
Published: August 2024

Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
Figure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Authors: Fredon Maxime , Poussard Margaux , Biichlé Sabeha , Bonnefoy Francis , Mantion Charles-Frédéric , Seffar Evan , Renosi Florian , Bôle-Richard Elodie , Boidot Romain , Chevrier Sandrine , Anna François , Loustau Maria , Caumartin Julien , Gonçalves-Venturelli Mathieu , Robinet Eric , Saas Philippe , Deconinck Eric , Daguidau Etienne , Roussel Xavier , Godet Yann , Adotévi Olivier , Angelot-Delettre Fanny , Galaine Jeanne , Garnache-Ottou Francine
Published: August 2024

Supplementary Figure S2: Characterization of CD123 CAR-T.
Figure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Authors: Fredon Maxime , Poussard Margaux , Biichlé Sabeha , Bonnefoy Francis , Mantion Charles-Frédéric , Seffar Evan , Renosi Florian , Bôle-Richard Elodie , Boidot Romain , Chevrier Sandrine , Anna François , Loustau Maria , Caumartin Julien , Gonçalves-Venturelli Mathieu , Robinet Eric , Saas Philippe , Deconinck Eric , Daguidau Etienne , Roussel Xavier , Godet Yann , Adotévi Olivier , Angelot-Delettre Fanny , Galaine Jeanne , Garnache-Ottou Francine
Published: August 2024

Supplementary Figure S1: Design of five CD123 CAR-T constructs.
Supplementary Figure S16 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
Authors: Teo Pei Y. , Jung Youngrock , Quach David H. , Koh Joanna , Ong Richard W. , Goh Angeline , Tan Alrina , Ng Chee H. , Seh Cheah C. , Tan Kar W. , Horak Ivan D. , Low Lionel
Published: August 2024

Supplementary Figure S16. Effects of SB9 overexpression on the exhaustion status of CD30.CAR with 4-1BB spacer (CD30.bb) or CD19.CAR TCRαβKO ATCs following sequential encounters with tumor cells as described in Fig. 5A. Effector CAR T cells were co-cultured with HLADKO NALM6-CD30 tumor cells, at a fixed ratio of 1:1 or 1:5, when CD30.bb TCRKO ATCs (A) or CD19.CAR TCRKO ATCs (B) were studied. PD-1, TIM-3 and LAG-3 expression on effector cells before the start of co-culture (Day 0) and on the last day of co-culture.
Table S12 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Authors: Meng Wei , Takeuchi Yoshiko , Ward Jeffrey P. , Sultan Hussein , Arthur Cora D. , Mardis Elaine R. , Artyomov Maxim N. , Lichti Cheryl F. , Schreiber Robert D.
Published: August 2024

Top 25 I-Ab binding 1956 neoantigens.
Table S11 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Authors: Meng Wei , Takeuchi Yoshiko , Ward Jeffrey P. , Sultan Hussein , Arthur Cora D. , Mardis Elaine R. , Artyomov Maxim N. , Lichti Cheryl F. , Schreiber Robert D.
Published: August 2024

Top 20 predicted H-2Db restricted neoepitopes of 1956 sarcomas.
Figure S8 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Authors: Meng Wei , Takeuchi Yoshiko , Ward Jeffrey P. , Sultan Hussein , Arthur Cora D. , Mardis Elaine R. , Artyomov Maxim N. , Lichti Cheryl F. , Schreiber Robert D.
Published: August 2024

F244 neoantigen tetramer staining and neoantigen targeting vaccines in F244 bearing mice.
Figure S4 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Authors: Meng Wei , Takeuchi Yoshiko , Ward Jeffrey P. , Sultan Hussein , Arthur Cora D. , Mardis Elaine R. , Artyomov Maxim N. , Lichti Cheryl F. , Schreiber Robert D.
Published: August 2024

Optimal FAIMS CV(s) improve the detection of T3 I-Ab restricted neoantigen mItgb1.
Figure S3 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Authors: Meng Wei , Takeuchi Yoshiko , Ward Jeffrey P. , Sultan Hussein , Arthur Cora D. , Mardis Elaine R. , Artyomov Maxim N. , Lichti Cheryl F. , Schreiber Robert D.
Published: August 2024

Optimal FAIMS CV(s) improve the coverage of I-Ab restricted peptides.
Supplementary Figure S4 from mTOR Signaling Promotes Rapid m6A mRNA Methylation to Regulate NK-Cell Activation and Effector Functions
Authors: Meng Meng , Zhong Zhaoyang , Song Liang , Zhang Zhaohui , Yin Xiaofeng , Xie Xiqiang , Tian Lei , Wu Wei , Yang Yao , Deng Yafei , Peng Hongyan , Wu Shuting , Ran Guanghe , Lin Yuqing , Lai Qiangqiang , Bi Qinghua , Yan Fulin , Ji Yan , Wang Yang , Li Xiaohui , Yi Ping , Yu Jianhua , Deng Youcai
Published: August 2024

Supplementary Figure S4
Supplementary Figure S3 from mTOR Signaling Promotes Rapid m6A mRNA Methylation to Regulate NK-Cell Activation and Effector Functions
Authors: Meng Meng , Zhong Zhaoyang , Song Liang , Zhang Zhaohui , Yin Xiaofeng , Xie Xiqiang , Tian Lei , Wu Wei , Yang Yao , Deng Yafei , Peng Hongyan , Wu Shuting , Ran Guanghe , Lin Yuqing , Lai Qiangqiang , Bi Qinghua , Yan Fulin , Ji Yan , Wang Yang , Li Xiaohui , Yi Ping , Yu Jianhua , Deng Youcai
Published: August 2024

Supplementary Figure S3
Supplemental Figure 3 from T-Cell Expression of CXCL13 is Associated with Immunotherapy Response in a Sex-Dependent Manner in Patients with Lung Cancer
Authors: Brennan Michelle , DeBruin David , Nwokolo Chinye , Hunt Katey S. , Piening Alexander , Donlin Maureen J. , Ferris Stephen T. , Teague Ryan M. , DiPaolo Richard J. , Alspach Elise
Published: August 2024

Supplemental Figure 3: Characterization of CD4+ and CD8+ T cell populations infiltrating tumors from male and female patients with NSCLC from Liu et al.
Supplementary Tables S1-S6 from Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway
Authors: Lv Qiaoying , Su Tong , Liu Wei , Wang Lulu , Hu Jiali , Cheng Yali , Ning Chengcheng , Shan Weiwei , Luo Xuezhen , Chen Xiaojun
Published: August 2024

Supplementary Tables S1-S6
Supplementary Figure S5 from Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway
Authors: Lv Qiaoying , Su Tong , Liu Wei , Wang Lulu , Hu Jiali , Cheng Yali , Ning Chengcheng , Shan Weiwei , Luo Xuezhen , Chen Xiaojun
Published: August 2024

Figure S5. ApoA1 potentiates CD8 + T-cell immune function via the HIF1α–mediated glycolysis pathway (related to Figure 5)
Supplementary Figure S2 from Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway
Authors: Lv Qiaoying , Su Tong , Liu Wei , Wang Lulu , Hu Jiali , Cheng Yali , Ning Chengcheng , Shan Weiwei , Luo Xuezhen , Chen Xiaojun
Published: August 2024

Supplementary Figure S2. Low serum ApoA1 impairs CD8 + T-cell tumor infiltration and cytotoxicity (related to Figure 2)
Supplementary Figure S1 from Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway
Authors: Lv Qiaoying , Su Tong , Liu Wei , Wang Lulu , Hu Jiali , Cheng Yali , Ning Chengcheng , Shan Weiwei , Luo Xuezhen , Chen Xiaojun
Published: August 2024

Supplementary Figure S1. Serum lipid level in ovarian cancer and endometrial cancer patients (related to Figure 1)
Data from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Authors: Siddiqui Bilal A. , Palaskas Nicolas L. , Basu Sreyashi , Dai Yibo , He Zhong , Yadav Shalini S. , Allison James P. , Sheth Rahul A. , Tummala Sudhakar , Buja Maximilian , Bhattacharjee Meenakshi B. , Iliescu Cezar , Rawther-Karedath Anishia , Deswal Anita , Wang Linghua , Sharma Padmanee , Subudhi Sumit K.
Published: August 2024

Abstract
Immune checkpoint therapies (ICT) can induce life-threatening immune-related adverse events, including myocarditis and myositis, which are rare but often concurrent. The molecular pathways and immune subsets underlying these toxicities remain poorly understood. To address this need, we performed single-cell RNA sequencing of heart and skeletal muscle biopsies obtained from living patients with cancers treated with ICTs and admitted to the hospital with myocarditis and/or myositis (overlapping myocarditis plus myositis, n = 10; myocarditis-only, n = 1) or ICT-exposed patients ruled out for toxicity utilized as controls (n = 9). All biopsies were obtained within 96 hours of clinical presentation. Analyses of 58,523 cells revealed CD8+ T cells with a cytotoxic phenotype expressing activation/exhaustion markers in both myocarditis and myositis. Furthermore, the analyses identified a population of myeloid cells expressing tissue-resident signatures and FcγRIIIa (CD16a), which is known to bind IgG and regulate complement activation. Immunohistochemistry of affected cardiac and skeletal muscle tissues revealed protein expression of pan-IgG and complement product C4d, which were associated with the presence of high-titer serum autoantibodies against muscle antigens in a subset of patients. We further identified a population of inflammatory IL1B+TNF+ myeloid cells specifically enriched in myocarditis and associated with greater toxicity severity and poorer clinical outcomes. These results provide insight into the myeloid subsets present in human immune-related myocarditis and myositis tissues and nominate new targets for investigation into rational treatments to overcome these high-mortality toxicities.

See related Spotlight by Fankhauser et al., p. 954
Data from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
Authors: Teo Pei Y. , Jung Youngrock , Quach David H. , Koh Joanna , Ong Richard W. , Goh Angeline , Tan Alrina , Ng Chee H. , Seh Cheah C. , Tan Kar W. , Horak Ivan D. , Low Lionel
Published: August 2024

Abstract
Allogeneic chimeric antigen receptor (CAR)–expressing T cells offer many advantages over autologous therapies, but their benefits are curtailed by graft-versus-host disease and elimination by recipient immune cells. Moreover, just as with autologous therapies, allogeneic CAR T cells are susceptible to activation-induced cell death (AICD) caused by chronic antigen exposure (CAE). Granzyme B– and Fas/Fas ligand–initiated caspase-mediated apoptoses are key mechanisms of T-cell death caused by T/NK cell–mediated allorejection or CAE. We explored a protective strategy of engineering CAR T cells to overexpress variants of the Granzyme B–specific serine protease inhibitor SERPINB9 (SB9) to improve allogeneic T-cell persistence and antitumor efficacy. We showed that the overexpression of an SB9 variant with broadened caspase specificity, SB9(CAS), not only significantly reduced rejection of allogeneic CAR T cells but also increased their resistance to AICD and enabled them to thrive better under CAE, thus improving allogeneic T-cell persistence and antitumor activity in vitro and in vivo. In addition, although SB9(CAS) overexpression improved the efficacy of allogeneic CAR T-cell therapy by conferring protection to cell death, we did not observe any autonomous growth, and the engineered CAR T cells were still susceptible to an inducible suicide switch. Hence, SB9(CAS) overexpression is a promising strategy that can strengthen current development of cell therapies, broadening their applications to address unmet medical needs.
Data from mTOR Signaling Promotes Rapid m6A mRNA Methylation to Regulate NK-Cell Activation and Effector Functions
Authors: Meng Meng , Zhong Zhaoyang , Song Liang , Zhang Zhaohui , Yin Xiaofeng , Xie Xiqiang , Tian Lei , Wu Wei , Yang Yao , Deng Yafei , Peng Hongyan , Wu Shuting , Ran Guanghe , Lin Yuqing , Lai Qiangqiang , Bi Qinghua , Yan Fulin , Ji Yan , Wang Yang , Li Xiaohui , Yi Ping , Yu Jianhua , Deng Youcai
Published: August 2024

Abstract
NK cells can be rapidly activated in response to cytokines during host defense against malignant cells or viral infection. However, it remains unclear what mechanisms precisely and rapidly regulate the expression of a large number of genes involved in activating NK cells. In this study, we discovered that NK-cell N6-methyladenosine (m6A) methylation levels were rapidly upregulated upon short-term NK-cell activation and were repressed in the tumor microenvironment (TME). Deficiency of methyltransferase-like 3 (METTL3) or METTL14 moderately influenced NK-cell homeostasis, while double-knockout of METTL3/14 more significantly impacted NK-cell homeostasis, maturation, and antitumor immunity. This suggests a cooperative role of METTL3 and METTL14 in regulating NK-cell development and effector functions. Using methylated RNA immunoprecipitation sequencing, we demonstrated that genes involved in NK-cell effector functions, such as Prf1 and Gzmb, were directly modified by m6A methylation. Furthermore, inhibiting mTOR complex 1 activation prevented m6A methylation levels from increasing when NK cells were activated, and this could be restored by S-adenosylmethionine supplementation. Collectively, we have unraveled crucial roles for rapid m6A mRNA methylation downstream of the mTOR complex 1–S-adenosylmethionine signal axis in regulating NK-cell activation and effector functions.
Supplementary Table S1 from p300 KAT Regulates SOX10 Stability and Function in Human Melanoma
Authors: Waddell Aaron , Grbic Nicole , Leibowitz Kassidy , Wyant William Austin , Choudhury Sabah , Park Kihyun , Collard Marianne , Cole Philip A. , Alani Rhoda M.
Published: August 2024

EP300 amplification frequencies in several acral melanoma datasets.
Supplementary Figure S7 from p300 KAT Regulates SOX10 Stability and Function in Human Melanoma
Authors: Waddell Aaron , Grbic Nicole , Leibowitz Kassidy , Wyant William Austin , Choudhury Sabah , Park Kihyun , Collard Marianne , Cole Philip A. , Alani Rhoda M.
Published: August 2024

This figure illustrates the acetylation sites in SOX10 and how SOX10 protein but not mRNA levels decrease with p300 inhibition.
Figure 5 from p300 KAT Regulates SOX10 Stability and Function in Human Melanoma
Authors: Waddell Aaron , Grbic Nicole , Leibowitz Kassidy , Wyant William Austin , Choudhury Sabah , Park Kihyun , Collard Marianne , Cole Philip A. , Alani Rhoda M.
Published: August 2024

A-485 potently inhibits proliferation of SOX10+ melanoma cell lines. A, A panel of melanoma cell lines were treated with A-485 (in a range of doses) for 6 days, and their relative proliferation vs. control was assessed (left). The results for 5 µmol/L A-485 vs. control are shown (right). B, Cells that did not respond to A-485 within 6 days were pretreated with 5 µmol/L A-485 for 9 days and reseeded for a 3-day proliferation assay, and their relative proliferation vs. control was assessed (total 12 days of drug treatment). C, WM983B-R and SK-Mel-28-R BRAFi-resistant cells have low expression of SOX10 in comparison with parental cells. D, The proliferation effects of short-term (6-day) or long-term (12-day) A-485 treatment of WM983B-R and SK-Mel-28-R cells were assessed. E, 451Lu-R cells maintain SOX10 expression vs. BRAFi-sensitive parental cells (left). 451Lu-S and 451Lu-R were treated with A-485 (in a range of doses) for 6 days, and their relative proliferation vs. control was assessed (right). F, A375-R cells maintain SOX10 expression vs. BRAFi-sensitive parental cells (left). A375-S and A375-R cells were treated with A-485 (in a range of doses) for 6 days, and their relative proliferation vs. control was assessed (middle). A375-S and A375-R cells were pretreated 5 µmol/L A-485 for 9 days and reseeded for a 3-day proliferation assay, and their relative proliferation vs. control was assessed (right). G, EP300 dependency scores are plotted for melanoma cell lines with low SOX10 [<4 log2(TPM + 1)] vs. high SOX10 [>4 log2(TPM + 1)] expression in the CDM 22Q2 public + score, Chronos dataset. *, P < 0.05; **, P < 0.005; ***, P < 0.0005.
Figure 1 from p300 KAT Regulates SOX10 Stability and Function in Human Melanoma
Authors: Waddell Aaron , Grbic Nicole , Leibowitz Kassidy , Wyant William Austin , Choudhury Sabah , Park Kihyun , Collard Marianne , Cole Philip A. , Alani Rhoda M.
Published: August 2024

EP300 is commonly co-amplified with SOX10 in melanomas. A, The EP300 and SOX10 genes are located in close proximity on chromosome 22. B,EP300 and SOX10 amplification prevalence in different melanoma datasets [TCGA, Dana Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center (MSKCC)]. Acral patients from multiple datasets were combined (combined acral). Amplification levels were defined using GISTIC2.0. C,EP300 (left) and SOX10 (right) expressions were analyzed for each copy-number level, as defined by GISTIC2.0 (data from TCGA; Del, deletion; D, diploid; low, low-level amplification; high, high-level amplification). Statistical analysis is compared with diploid samples. D,EP300 and SOX10 copy numbers are positively correlated in melanoma cell lines (data from the CDM). E,EP300 copy number and expression are positively correlated in melanoma cell lines (left). SOX10 copy number and expression are positively correlated in melanoma cell lines (right; data CDM). F,EP300/SOX10 co-amplifications (>2 copies of EP300 and SOX10) are common in melanoma cell lines (data from CDM). *, P < 0.05; **, P < 0.005; ***, P < 0.0005.
Feasibility and Success of Muscular Ventricular Septal Defect Occluders and Mushroom-Shaped Occluders in Transcatheter Patent Ductus Arteriosus Closure in Low-Weight Children: A Propensity Score-Matched Retrospective Analysis from a Chinese National Regional Health Center
Authors: Zhang Kaijun , Yang Le , Zhang Rensen , Ma Jingdong , Cheng Min , Yang Penghui , Xiang Ping , Li Mi , Zhou Xue
Published: August 2024

Introduction: Muscular ventricular septal defect occluders (MVSDOs) have been attempted as an option in low-weight patients with patent ductus arteriosus (PDA). However, few studies have assessed the safety of transcatheter patent ductus arteriosus closure (TCPC) using MVSDO. Therefore, we compared the outcomes in low-weight patients who used MVSDO and mushroom-shaped occluder (MSO). Methods: Medical records of children under 10 kg (n = 417) who underwent TCPC from 2015 to 2021 at a Chinese health center were reviewed. They were divided into MSO (n = 372) and MVSDO (n = 45) groups. A 1:1 propensity score matching (PSM) was done considering gender, height, weight, body surface area (BSA), PDA diameter, and BSA-corrected PDA diameter. Results: All 45 children in the MVSDO group (mean weight: 5.92 ± 1.32 kg) achieved successful immediate occlusion. One case in the MVSDO group experienced device migration within 24 h requiring unplanned surgery. MVSDO significantly ameliorated pulmonary artery hypertension. After PSM, each group comprised 41 children. The MVSDO group had a smaller effect on platelet counts (MVSDO vs. MSO = 259.85 ± 114.82 vs. 356.12 ± 134.37, p < 0.001), a reduced incidence of thrombocytopenia (MVSDO vs. MSO = 2/41 vs. 7/41, p = 0.001), and a higher rate of residual shunting (MVSDO vs. MSO = 16/41 vs. 5/41, p = 0.005), compared with the MSO group. Thrombocytopenia resolved during hospitalization and micro-shunts disappeared by 6 months. No pulmonary artery or descending aortic secondary stenosis was observed in 1-year follow-up. Conclusions: MVSDO used in low-weight children is feasible, with high success and satisfactory postoperative and short-term follow-up outcomes, including lower thrombocytopenia incidence, compared to MSO. Further long-term studies with larger samples are recommended.
Association of Urinary Metals With Cardiovascular Disease Incidence and All-Cause Mortality in the Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Martinez-Morata Irene , Schilling Kathrin , Glabonjat Ronald A. , Domingo-Relloso Arce , Mayer Melanie , McGraw Katlyn E. , Galvez Fernandez Marta , Sanchez Tiffany R. , Nigra Anne E. , Kaufman Joel D. , Vaidya Dhananjay , Jones Miranda R. , Bancks Michael P. , Barr R. Graham , Shimbo Daichi , Post Wendy S. , Valeri Linda , Shea Steven , Navas-Acien Ana
Published: August 2024

BACKGROUND:

Exposure to metals has been associated with cardiovascular disease (CVD) end points and mortality, yet prospective evidence is limited beyond arsenic, cadmium, and lead. In this study, we assessed the prospective association of urinary metals with incident CVD and all-cause mortality in a racially diverse population of US adults from MESA (the Multi-Ethnic Study of Atherosclerosis).

METHODS:

We included 6599 participants (mean [SD] age, 62.1 [10.2] years; 53% female) with urinary metals available at baseline (2000 to 2001) and followed through December 2019. We used Cox proportional hazards models to estimate the adjusted hazard ratio and 95% CI of CVD and all-cause mortality by baseline urinary levels of cadmium, tungsten, and uranium (nonessential metals), and cobalt, copper, and zinc (essential metals). The joint association of the 6 metals as a mixture and the corresponding 10-year survival probability was calculated using Cox Elastic-Net.

RESULTS:

During follow-up, 1162 participants developed CVD, and 1844 participants died. In models adjusted by behavioral and clinical indicators, the hazard ratios (95% CI) for incident CVD and all-cause mortality comparing the highest with the lowest quartile were, respectively: 1.25 (1.03, 1.53) and 1.68 (1.43, 1.96) for cadmium; 1.20 (1.01, 1.42) and 1.16 (1.01, 1.33) for tungsten; 1.32 (1.08, 1.62) and 1.32 (1.12, 1.56) for uranium; 1.24 (1.03, 1.48) and 1.37 (1.19, 1.58) for cobalt; 1.42 (1.18, 1.70) and 1.50 (1.29, 1.74) for copper; and 1.21 (1.01, 1.45) and 1.38 (1.20, 1.59) for zinc. A positive linear dose-response was identified for cadmium and copper with both end points. The adjusted hazard ratios (95% CI) for an interquartile range (IQR) increase in the mixture of these 6 urinary metals and the corresponding 10-year survival probability difference (95% CI) were 1.29 (1.11, 1.56) and –1.1% (–2.0, –0.05) for incident CVD and 1.66 (1.47, 1.91) and –2.0% (–2.6, –1.5) for all-cause mortality.

CONCLUSIONS:

This epidemiological study in US adults indicates that urinary metal levels are associated with increased CVD risk and mortality. These findings can inform the development of novel preventive strategies to improve cardiovascular health.
Building Digital Twins for Cardiovascular Health: From Principles to Clinical Impact
Authors: Sel Kaan , Osman Deen , Zare Fatemeh , Masoumi Shahrbabak Sina , Brattain Laura , Hahn Jin‐Oh , Inan Omer T. , Mukkamala Ramakrishna , Palmer Jeffrey , Paydarfar David , Pettigrew Roderic I. , Quyyumi Arshed A. , Telfer Brian , Jafari Roozbeh
Published: August 2024

The past several decades have seen rapid advances in diagnosis and treatment of cardiovascular diseases and stroke, enabled by technological breakthroughs in imaging, genomics, and physiological monitoring, coupled with therapeutic interventions. We now face the challenge of how to (1) rapidly process large, complex multimodal and multiscale medical measurements; (2) map all available data streams to the trajectories of disease states over the patient's lifetime; and (3) apply this information for optimal clinical interventions and outcomes. Here we review new advances that may address these challenges using digital twin technology to fulfill the promise of personalized cardiovascular medical practice. Rooted in engineering mechanics and manufacturing, the digital twin is a virtual representation engineered to model and simulate its physical counterpart. Recent breakthroughs in scientific computation, artificial intelligence, and sensor technology have enabled rapid bidirectional interactions between the virtual‐physical counterparts with measurements of the physical twin that inform and improve its virtual twin, which in turn provide updated virtual projections of disease trajectories and anticipated clinical outcomes. Verification, validation, and uncertainty quantification builds confidence and trust by clinicians and patients in the digital twin and establishes boundaries for the use of simulations in cardiovascular medicine. Mechanistic physiological models form the fundamental building blocks of the personalized digital twin that continuously forecast optimal management of cardiovascular health using individualized data streams. We present exemplars from the existing body of literature pertaining to mechanistic model development for cardiovascular dynamics and summarize existing technical challenges and opportunities pertaining to the foundation of a digital twin.
Explicit or implicit digital humanities? An examination of search strategies to retrieve digital humanities publications from large-scale scholarly databases
Authors: Li Kai , Ma Rongqian , Fang Zhichao
Published: August 2024

As a growing research field, digital humanities (DH) is receiving increasing attention from quantitative science studies using standardized scholarly databases. However, one of the challenges of this new line of research is how to select the query strategy to produce a representative sample of the field. In this research, we analyzed the differences between two publication samples acquired from the Dimensions database using two sampling approaches, namely, a keyword search and a DH journal list. We argue that these two samples offer distinct perspectives on the conceptual landscape of digital humanities, namely, implicit DH and explicit DH, and contribute to building a more comprehensive representation of the DH research domain. We identified notable differences between the publication samples from these two query strategies, especially the fact that these two samples have a very small overlap of publications, and they also have different disciplinary orientations. Our findings indicate that future quantitative studies analyzing DH publications should use more inclusive methods to cover both the implicit and explicit types of DH contributions. Moreover, we also discussed how our findings contribute to a deeper understanding of the disciplinary composition of DH, an interdisciplinary research field.
The Tang Dynasty Origins of Song Technocracy
Authors: Hartman Charles
Published: August 2024

The influential Naitō-Hartwell hypothesis of middle period Chinese history posits an economic and social transformation from the aristocratic-led early Tang (618–907 CE) period to the literati and gentry-led governance of Song (960–1279 CE). Fundamental to this thesis is the drastic economic expansion that unfolded during these centuries. However, scholars have devoted less attention to how these larger economic and demographic trends relate to both continuity and change in the monarchies of this period. In the aftermath of the An Lushan 安祿山 (753–763 CE) rebellion, the Six Dynasties (220–589 CE) and early Tang conception of emperorship as a ritual primus inter pares among aristocratic peers gave way to a new conception of the monarchy as the command center of a technocratic corporation. This article describes the late Tang and Five Dynasties (907–979 CE) institutional and political structures that the Song founders, descendants of the independent and entrepreneurial Hebei military administrators of the ninth century, inherited and adapted to develop this new model of imperial governance. As the Song moved into the eleventh century, only this new entrepreneurial monarchy, an imperial technocracy, possessed the administrative capacity and technological competencies necessary to capitalize and harness the period’s transformative economic forces.
A Torah Manuscript from Iran from the End of the Fifteenth Century with Haftarot and Psalms
Authors: Kolodni Orlit
Published: August 2024

This article analyzes a paper manuscript, containing the Pentateuch, Haftarot and Psalms. Only five medieval Persian Pentateuch manuscripts have survived, four from the fifteenth century and one from the sixteenth century. The selected manuscript is one of the four surviving manuscripts from the fifteenth century (1483–1484). It is the earliest surviving manuscript from Iran from the Middle Ages that includes the Pentateuch, the Haftarot, and the Psalms with vowel points, accents, Masorah magna and parva. A comparison of the manuscript with the Aleppo Codex and with five traditions from different regions (accurate Oriental Masoretic codices, Yemenite manuscripts, Sefardi manuscripts, Ashkenazi manuscripts, and Italian manuscripts) shows that this fifteenth-century manuscript written in Central Asia preserves and represents an ancient tradition with respect to the text, sections, and the Songs that is similar to the accurate Oriental Masoretic Pentateuchs. Our manuscript is witness to an ancient tradition that preserves a very accurate text in the Iranian region, and is close to the Aleppo Codex, and similar to Oriental manuscripts of the tenth and eleventh centuries written in the East, without alternate traditions that corrupted the text.
A Postlaunch Update on the Effects of Instrumental Measurement Errors on SWOT Estimates of Sea Surface Height, Velocity, and Vorticity
Authors: Chelton Dudley B.
Published: August 2024

The Ka-band radar interferometer (KaRIn) on the Surface Water and Ocean Topography (SWOT) satellite that was launched in December 2022 is providing the first two-dimensional altimetric views of sea surface height (SSH). Measurements are made across two parallel swaths of 50-km width separated by a 20-km gap. In the data product that will be used for most oceanographic applications, SSH estimates with a footprint diameter of about 3 km are provided on a 2 km × 2 km grid. Early analyses of in-flight KaRIn data conclude that the instrumental noise for this footprint diameter has a standard deviation less than σ3km = 0.40 cm for conditions of 2-m significant wave height. This is a factor of 2.3 better than the prelaunch expectation based on the science requirement specification. The SSH fields measured by KaRIn allow the first satellite estimates of essentially instantaneous surface current velocity and vorticity computed geostrophically from SSH. The effects of instrumental noise on smoothed estimates of velocity and vorticity based on early postlaunch assessments are quantified here as functions of the half-power filter cutoff wavelength of the smoothing. Signal-to-noise ratios for smoothed estimates of velocity and vorticity are determined from simulated noisy KaRIn data derived from a high-resolution numerical model of the California Current System. The wavelength resolution capabilities for σ3km = 0.40 cm are found to be about 17 and 35 km for velocity and vorticity, respectively, which correspond to feature diameters of about 8.5 and 17.5 km, and are better than the prelaunch expectations by about 45% and 35%.
A Hybrid Type III Analysis of a Filmed Story-Telling Intervention’s Impact on Provider Stigma
Authors: Wasmuth Sally , Belkiewitz Johnna , Miech Edward , Li Chih-Ying , Harris Alex , Hernandez Jocelyne , Horsford Caitlin , Smith Carlton , Bravata Dawn
Published: August 2024

Identity Development Evolution and Sharing (IDEAS) reduces provider stigma, but few have been trained to implement IDEAS, highlighting a need for implementation strategies that facilitate uptake. We evaluated whether external facilitation successfully supported IDEAS implementation and whether IDEAS reduced provider stigma within and across sites irrespective of implementation barriers and facilitators. Key informants from 10 sites completed interviews and surveys of appropriateness, acceptability, and feasibility. Interviews were analyzed using the Consolidated Framework for Implementation Research guidelines. Intervention effectiveness was measured via paired t tests of pre-/post-quantitative data on provider stigma completed by practitioners who attended the training. Ten sites successfully implemented IDEAS via external facilitation; 58 practitioners from nine sites completed pre- and post-surveys. Data showed significant decreases in stigma after the intervention. IDEAS, supported by external facilitation, is a feasible, acceptable, and appropriate means of reducing stigma among occupational therapy practitioners.